Novavax Inc. stock underperforms Wednesday when compared to competitors | news.google.com • |
Novavax Inc. stock underperforms Wednesday when compared to competitors | news.google.com • |
Shah Capital Management Acquires 1,544,263 Shares of Novavax, Inc. (NASDAQ:NVAX) | news.google.com • |
Novavax Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
Novavax Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
Novavax Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-08 | 2024-06 | 1.82 | 0.99 | -0.83 | -45.60% |
2024-05-10 | 2024-03 | -1.04 | -1.05 | -0.01 | -0.96% |
2024-02-28 | 2023-12 | -0.49 | -1.44 | -0.95 | -193.88% |
2023-11-09 | 2023-09 | -1.82 | -1.26 | 0.56 | 30.77% |
2023-08-08 | 2023-06 | -1.24 | 0.58 | 1.82 | 146.77% |
2023-05-09 | 2023-03 | -3.38 | -3.41 | -0.03 | -0.89% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-08 | B. Riley Securities | Upgrade | Neutral | Buy |
2023-05-09 | HC Wainwright & Co. | Upgrade | Buy | |
2023-02-28 | B. Riley Securities | Downgrade | Buy | Neutral |
2023-02-12 | HC Wainwright & Co. | Upgrade | Buy | |
2023-01-01 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-06-11 | ALTON GREGG H | Director | 10.47K | Conversion of Exercise of derivative security |
2024-06-11 | DOUGLAS RICHARD H | Director | 43.92K | Conversion of Exercise of derivative security |
2024-06-16 | DUBOVSKY FILIP | Officer | 66.61K | Sale |
2024-08-15 | KELLY JAMES PATRICK | Chief Financial Officer | 14.43K | Conversion of Exercise of derivative security |
2024-06-11 | KING RACHEL K | Director | 18.92K | Conversion of Exercise of derivative security |
2024-06-11 | MCGLYNN MARGARET G | Director | 10.47K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | State Street Corporation | 11.68M | 86.78M | 12.37% |
2023-06-29 | Vanguard Group Inc | 10.57M | 78.55M | 11.20% |
2023-06-29 | Blackrock Inc. | 6.99M | 51.97M | 7.41% |
2023-09-29 | Shah Capital Management | 6.33M | 45.83M | 6.71% |
2023-06-29 | Bank of America Corporation | 2.18M | 16.23M | 2.31% |
2023-06-29 | Morgan Stanley | 2.08M | 15.46M | 2.20% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 9.38M | 75.07M | 9.94% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 2.64M | 19.60M | 2.79% |
2023-06-29 | Vanguard Small-Cap Index Fund | 2.23M | 16.56M | 2.36% |
2023-08-30 | iShares Russell 2000 ETF | 2.01M | 16.10M | 2.13% |
2023-06-29 | Vanguard Small-Cap Growth Index Fund | 1.28M | 9.48M | 1.35% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.21M | 8.98M | 1.28% |
Split | Date |
---|---|
1 : 20 | 2019-05-10 |
-
Right now sentiment is as poor as you can get - all the hoopla about the pandemic being over - it was like when oil went negative - I think you will be surprised when this all plays out - cycles are in place and will occur
-
So many people on this board have no idea what you have to do to grow in today’s public market - put your shares in the bank box, come back in a year and see what they are worth- I bet the answer will be substantially higher - variants are coming and NOVX will keep having bigger revenue and profits - all the people like Lauren love the moment - egos like hers are what makes all this a game - she better start covering her shorts! The short game is over - hopefully she moves onto another space in the market, maybe energy
-
I believe that this is a very young and small company working very hard to make revenues and profits - it is not easy to compete against PFE and the other companies that have had the marketers in place for many years - it takes some time for this to occurred and I believe that the 1Q was a first for the company - maybe they didn’t meet expectations but they are growing and will continue to grow - FDA approval coming and better quarters on the horizon - haters should just quit kicking a young big in the big world - he will grow and take on the bigger ones in the coming years - they are not going broke and no reason for people to pound their cheats saying “I told you so!” I believe buying NOVX makes sense on the weakness tomorrow- probably margin selling and shorts hitting it ( but that play is over!)
-
-
$NVAX. I own a bunch of this at $80. I think it should have no trouble getting back past that and I am not the only one:
“Novavax, Inc. (NASDAQ:NVAX – Get Rating) – Equities research analysts at Cantor Fitzgerald decreased their FY2022 earnings per share estimates for Novavax in a note issued to investors on Tuesday, April 26th. Cantor Fitzgerald analyst C. Duncan now expects that the biopharmaceutical company will post earnings per share of $9.06 for the year, down from their previous estimate of $13.08. Cantor Fitzgerald has a “Overweight” rating and a $174.00 price target on the stock.” -
At this point in the NVAX world, you have to stop watching and let Mgmt dictate eps projections - that will be the only way the stock moves higher - right now sentiment has the stock weaker as poorer numbers are expected - guidance will be key - the pandemic is over - of course another variant run with deadly consequences would move the stock as well - shorts had the perfect stock - longs just held on expecting one last run - I would expect the stock to trade around $42-$50/ share until eps release
-
-
@AI Y , who gives a f!!!! about approvals… you pumper!!!
-
$NVAX I’m too busy to make a chart showing timelines for trials and approvals vs. mRNA gene therapies from $PFE $BNTX $MRNA but what would be really exciting is the lack of side effects in Novavax’s protein based traditional vaccine.
Then I guess we would have to note why the USFDA has let 42 countries approve the safe alternative while still demanding the military and hospitals “mRNA vaccinate”. If I had to guess who is shorting this stock…
-
-
Can’t wait for ER!!
-
Pumper AI Y never gives up with his garbage!!
-
The market cap is at this year’s projected revenue. This is silly!
-
The market cap is at this year’s projected revenue. This is silly!
-
$NVAX RE my request for FDA presentation lost audio info just never mind, WOW! The FDA can’t even manage a video conference and I’m 4hrs. in . How are they managing to “keep us safe” much less approve this vaccine. ️
-
$NVAX Min1:25:20 audio is completely cut. Anyone who watched live know what was the doctor said? https://youtu.be/x8rq247E80I
-
-
Novavax Inc. stock underperforms Wednesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Wednesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Tuesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Tuesday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Tuesday when compared to competitors
news.google.com • -
Why Novavax is Gaining Ground in COVID-19 Vaccine Race
news.google.com • -
Novavax Inc. stock underperforms Monday when compared to competitors
news.google.com • -
Novavax Inc. stock underperforms Monday when compared to competitors
news.google.com • -
(NVAX) Trading Report
news.google.com • -
Novavax Inc. stock outperforms competitors on strong trading day
news.google.com • -
Should You Buy Novavax Stock After This Regulatory Win?
news.google.com • -
Should You Buy Novavax Stock After This Regulatory Win?
news.google.com • -
Novavax Inc. stock underperforms Thursday when compared to competitors
news.google.com • -
Why Are Novavax Shares Trading Lower Today?
news.google.com •